Evidence map›Paper›PMID 42432755›Full record

ArticleBreast cancer research : BCR2026

Visceral adiposity and breast cancer outcomes: transcriptomic analysis of the tumor microenvironment by intrinsic subtype.

Anlan Cao, Sophia Fuller, Jorge Gómez Tejeda Zañudo, Wendy Y Chen, Deborah Dillon, Sandra McAllister, Elizabeth A Mittendorf, Rinath Jeselsohn, Bette J Caan, Charles Quesenberry and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anlan CaoDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Sophia FullerDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Jorge Gómez Tejeda ZañudoDana-Farber Cancer Institute, Boston, MA, USA.
Wendy Y ChenDana-Farber Cancer Institute, Boston, MA, USA.
Deborah DillonDana-Farber Cancer Institute, Boston, MA, USA.
Sandra McAllisterHarvard Medical School, Boston, MA, USA.
Elizabeth A MittendorfDana-Farber Cancer Institute, Boston, MA, USA.
Rinath JeselsohnDana-Farber Cancer Institute, Boston, MA, USA.
Bette J CaanDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Charles QuesenberryDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA. elizabeth.m.cespedes@kp.org.

Funding

Body composition and breast cancer survival: immune and metabolic biomarkers in breast tumors - Disparities SupplementR01CA251589 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI FELICIANO, ELIZABETH MARJORIE CESPEDES · 2020 to 2025
$3.5M
NCI NIH HHS R01 CA251589NCI NIH HHS R01CA251589
6 · The paper itself

Abstract

backgroundObesity is linked to poor breast cancer outcomes, but evidence within molecular intrinsic subtypes is limited. We measured visceral and subcutaneous adipose tissue (VAT and SAT) on routine clinical imaging and examined survival and tumor microenvironment (TME) differences across PAM50 subtypes.

methodsWe sampled 1,377 individuals diagnosed with stage II-III breast cancer at Kaiser Permanente Northern California between 2005 and 2015, enriched for HER2 + and ER- tumors. VAT and SAT areas (cm

resultsParticipants had a mean (± SD) age of 56 ± 13 years. Intrinsic subtype distribution was: Basal-like (31%), HER2-E (25%), Luminal B (22%), and Luminal A (22%). Over a median follow-up of 11 years, patients with HER2-E tumors and high-VAT had higher breast cancer-specific mortality (HR = 2.14, 95%CI 1.25-3.65) and distant relapse (HR = 2.05, 95%CI 1.23-3.42). No VAT associations were observed in other subtypes. Transcriptomic analyses revealed enhanced abundance of cancer-associated fibroblasts (CAF) with corresponding stromal signatures exclusively in high-VAT HER2-E tumors. Higher CAF and stromal activation signatures were associated with worse outcomes in the full cohort. SAT showed no associations in any subtype.

conclusionsVisceral adiposity identified a high-risk subset of HER2-E breast cancer characterized by high CAF and stromal activation signatures and inferior survival, highlighting an opportunity for VAT-targeted interventions and mechanistic studies to clarify adiposity-TME interactions.

Indexed as

AdiposityBreast NeoplasmsIntra-Abdominal FatTranscriptomeTumor MicroenvironmentAdultAgedBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBody compositionBreast cancerSurvivalTumor microenvironment

Identifiers

PMID42432755
PMCPMC13637348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.